uracil has been researched along with Acute Coronary Syndrome in 19 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The EXAMINE trial confirmed noninferiority of the dipeptidyl dipeptidase 4 inhibitor alogliptin to placebo on major adverse cardiac event rates in a post-acute coronary syndrome (ACS) T2DM population." | 9.22 | Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care tria ( Bakris, GL; Cannon, CP; Cushman, WC; Kupfer, S; Liu, Y; Mehta, CR; Menon, V; Shimada, YJ; White, WB; Wilson, C; Zannad, F, 2016) |
| "In patients with type 2 diabetes and recent acute coronary syndromes, alogliptin did not increase the risk of heart failure outcomes." | 9.20 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F, 2015) |
| "Approximately 5,400 men and women with type 2 diabetes and ACS (acute myocardial infarction or unstable angina) are being recruited and will be followed up for up to 4." | 6.76 | EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients wi ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Fleck, P; Heller, S; Mehta, C; Nissen, SE; Perez, A; White, WB; Wilson, C; Zannad, F, 2011) |
| "Patients with type 2 diabetes and recent acute coronary syndrome were randomized to alogliptin or placebo and standard of care." | 5.27 | Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. ( Bergenstal, RM; Cannon, CP; Heller, SR; Howitt, H; Khunti, K; White, WB, 2018) |
| "The EXAMINE trial randomized 5380 patients with type 2 diabetes (T2DM) and a recent acute coronary syndrome (ACS) event, in 49 countries, to double-blind treatment with alogliptin or placebo in addition to standard of care." | 5.24 | Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Gourlie, NM; Heller, SR; Kupfer, S; Liu, Y; Mehta, CR; Nissen, SE; White, WB; Wilson, CA; Zannad, F, 2017) |
| " The EXAMINE trial confirmed noninferiority of the dipeptidyl dipeptidase 4 inhibitor alogliptin to placebo on major adverse cardiac event rates in a post-acute coronary syndrome (ACS) T2DM population." | 5.22 | Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care tria ( Bakris, GL; Cannon, CP; Cushman, WC; Kupfer, S; Liu, Y; Mehta, CR; Menon, V; Shimada, YJ; White, WB; Wilson, C; Zannad, F, 2016) |
| "In patients with type 2 diabetes and recent acute coronary syndromes, alogliptin did not increase the risk of heart failure outcomes." | 5.20 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F, 2015) |
| "The EXAMINE trial included 5380 patients with T2D and a recent acute coronary syndrome, who were randomized to alogliptin or placebo." | 4.02 | Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. ( Bakris, G; Ferreira, JP; Mehta, C; Rossignol, P; White, WB; Zannad, F, 2021) |
| "Alogliptin did not increase the risk of either first or recurrent CV events when compared with placebo in patients with T2DM and recent acute coronary syndrome." | 2.87 | Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome. ( Bergenstal, RM; Cannon, CP; Cavender, MA; Cushman, WC; Heller, S; Liu, Y; Massaro, JM; Mehta, CR; White, WB; Zannad, F, 2018) |
| "Early after an ACS, patients with type 2 diabetes mellitus experience a significant burden of HF events and recurrent ACS." | 2.87 | Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Liu, Y; Sharma, A; White, WB; Zannad, F, 2018) |
| "Patients with type 2 diabetes mellitus, glycohemoglobin between 6." | 2.84 | Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care). ( Bakris, GL; Cannon, CP; Cavender, MA; Cushman, WC; Gao, Q; Jarolim, P; Kupfer, S; Mehta, CR; Morrow, DA; White, WB; Zannad, F, 2017) |
| "Patients with type 2 diabetes mellitus and a recent acute coronary syndrome were randomly assigned to receive the dipeptidyl peptidase 4 inhibitor alogliptin or placebo added to existing antihyperglycemic and cardiovascular prophylactic therapies." | 2.82 | Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Heller, SK; Kupfer, S; Mehta, CR; Nissen, SE; White, WB; Wilson, CA; Zannad, F, 2016) |
| "Approximately 5,400 men and women with type 2 diabetes and ACS (acute myocardial infarction or unstable angina) are being recruited and will be followed up for up to 4." | 2.76 | EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients wi ( Bakris, GL; Bergenstal, RM; Cannon, CP; Cushman, WC; Fleck, P; Heller, S; Mehta, C; Nissen, SE; Perez, A; White, WB; Wilson, C; Zannad, F, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (84.21) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Ferreira, JP | 3 |
| Rossignol, P | 2 |
| Bakris, G | 2 |
| Mehta, C | 4 |
| White, WB | 14 |
| Zannad, F | 14 |
| Sharma, A | 3 |
| Vaduganathan, M | 1 |
| Liu, Y | 7 |
| Bakris, GL | 9 |
| Cannon, CP | 12 |
| Elharram, M | 1 |
| White, W | 1 |
| Hwang, YC | 1 |
| Morrow, DA | 3 |
| Bergenstal, R | 1 |
| Heller, S | 3 |
| Cushman, W | 1 |
| Heller, SR | 2 |
| Howitt, H | 1 |
| Khunti, K | 1 |
| Bergenstal, RM | 5 |
| Cavender, MA | 2 |
| Massaro, JM | 1 |
| Mehta, CR | 6 |
| Cushman, WC | 8 |
| Menon, V | 2 |
| Perez, AT | 1 |
| Fleck, PR | 1 |
| Kupfer, S | 6 |
| Wilson, C | 3 |
| Lam, H | 1 |
| Riche, DM | 1 |
| Davis, C | 1 |
| Derosa, G | 2 |
| Maffioli, P | 2 |
| Hülsmann, M | 1 |
| Pacher, R | 1 |
| Neuhold, S | 1 |
| Shimada, YJ | 1 |
| Wilson, CA | 2 |
| Heller, SK | 1 |
| Nissen, SE | 3 |
| Gourlie, NM | 1 |
| Bergmark, BA | 1 |
| Jarolim, P | 2 |
| Bonaca, MP | 1 |
| Gao, Q | 1 |
| Fleck, P | 1 |
| Perez, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome[NCT00968708] | Phase 3 | 5,380 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary Major Adverse Cardiac Events were defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 11.8 |
| Alogliptin | 11.3 |
Secondary MACE composite consisted of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent revascularization due to unstable angina; these events were adjudicated by an independent cardiovascular endpoint committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-of date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 13.4 |
| Alogliptin | 12.7 |
13 trials available for uracil and Acute Coronary Syndrome
6 other studies available for uracil and Acute Coronary Syndrome
| Article | Year |
|---|---|
Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial.
Topics: Acute Coronary Syndrome; Aged; Body Mass Index; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2021 |
EXAMINE: targeting risk and treatment in diabetes.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure | 2015 |
EXAMINE: targeting risk and treatment in diabetes.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure | 2015 |
EXAMINE: targeting risk and treatment in diabetes.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure | 2015 |
EXAMINE: targeting risk and treatment in diabetes - Authors' reply.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure | 2015 |
Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibi | 2016 |